Provectus Pharmaceuticals Inc. (PVCT.OB) Initiates Phase 1 Trial of Liver Cancer Drug
Provectus Pharmaceuticals Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of their drug – PV-10 – for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. The same drug is currently undergoing Phase 2 study for metastatic melanoma. The primary objective of the open-label study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with liver cancer. Additional objectives are to assess the distribution and retention of PV-10 in the injected lesion, tumor response and…